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Abstract 
 
A series of new derivatives of the natural β-carboline alkaloid harmine, introducing 
hydrophobic substituents into positions 7 and 9 were synthetized as potential anticancer 
agents. Their binding affinities for human serum albumin (HSA) and α1-acid-glycoprotein 
(AAG) were investigated by affinity chromatography combined with fluorescence, circular 
dichroism (CD) and UV absorption spectroscopy. The weak binding of harmine to both 
proteins (Ka ~ 3 × 10
4 M-1) was highly increased by aromatic substitutions (Ka ~ 10
5-106 M-1). 
Derivatives having a substituted benzyl group in the N9-position of the β-carboline nucleus 
showed about tenfold and hundred fold affinity enhancement for HSA and AAG, respectively. 
Such a strong plasma protein interaction would be of pharmacokinetic relevance for these 
potential drug candidates. Induced CD spectra indicated the variant selective, dimeric binding 
of the 7-pyridylethoxy derivative to AAG. Absorbance and fluorescence spectra refer to the 
binding preference of the neutral form of the studied β-carbolines for both proteins. 
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Introduction 
 
Harmine possessing a tricyclic pyrido[3,4-b]indole ring structure is a representative member 
of the naturally occurring β-carboline alkaloids. It was originally isolated from the seed of 
Peganum harmala and widely utilized for hundreds of years in the traditional Chinese 
medicine to treat alimentary tract cancer and malaria.1 This herbal substance is of great 
interest due to its diverse biochemical activities including DNA intercalation,1,2 inhibition of 
topoisomerase1 and cyclin-dependent kinases.1,3 Several studies demonstrated that it inhibits 
selectively monoamine oxidases,4 which play a key role in psychiatric and neurological 
disorders5 (depression and Parkinson’s diseases). Harmine was also identified as a potential 
inhibitor of the kinase Dyrk1A that is implicated in the pathogenesis of Down syndrome,6 a 
common hereditary disorder.  
In the past, numerous studies investigated the effect of harmine on the central nervous system 
such as its interaction with benzodiazepine, 5-HT2A, 5HT2C and imidazoline receptors. 
Recently, however, harmine and its ring-substituted derivatives attracted attention as potential 
cancer drugs. Ishida et al. evaluated7  the change in the antitumor activity of this alkaloid on 
the introduction of various substituents onto the β-carboline skeleton at positions 1, 2, 6, 7, 
and 9. Structure-activity relationship studies indicated that upon incorporation of appropriate 
alkyl and aralkyl groups in position 9, the antitumor effect of harmine against Lewis lung 
cancer and sarcoma 180 was dramatically enhanced. It was also proved8,9  that the neurotoxic 
side effect of these compounds can be decreased by replacing methoxy group at position 7. 
We performed the synthesis of a series of 7- and 9-substituted harmine derivatives (Scheme 1) 
in order to study their interaction with human serum proteins. 
Binding of drugs10 and natural products11,12 to blood plasma proteins influences their 
pharmacokinetic and pharmacodynamic action. Among human serum proteins, the most 
abundant albumin component (HSA) is of the highest importance13,14 , but no data are 
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available on the harmine-HSA interaction. HSA binding of the related β-carboline compound 
harmane (R7: H) was found to be weak15 (Ka ~ 2.4 × 10
4 M-1), while the binding of 
norharmane, lacking 1-methyl substitution, is much more pronounced (Ka ~ 1.7 × 10
5 M-1). 
Besides HSA, α1-acid glycoprotein (AAG) also plays a decisive role in the binding and 
transportation of a broad array of basic and neutral drug molecules.16,17 AAG association of β-
carbolines has not been evaluated though these molecules exist as a mixture of neutral and 
cationic forms at physiological pH. Thus, in this work we studied the binding of harmine and 
its derivatives to HSA and AAG. Since plasma AAG is a mixture of two main genetic variants 
with different drug binding abilities,18-21 the separated ‘F1/S’ and ‘A’ genetic variants were 
tested as well. The applied experimental methodologies include affinity chromatography, as 
well as fluorescence, circular dichroism, and UV absorption spectroscopic techniques. 
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Experimental details 
 
1. General methods 
1H, 13C and 19F NMR spectra were recorded on a Bruker Avance III 500 instrument. Chemical 
shifts are given in parts per million (ppm) and spectra are obtained as DMSO-d6 or CDCl3 
solutions, using chloroform (7.26 ppm) or DMSO-d6 (2.50 ppm) as the reference standard. 
The following abbreviations are used to denote signal multiplicities: s = singlet, d = doublet, t 
= triplet, m = multiplet, and br = broadened. All coupling constants (J) are given in hertz (Hz). 
Analytical HPLC was performed on Agilent 1200 Series utilizing Waters Acquity UPLC 
BEH C18, 2.1 × 30 mm, 1.7 µm column (solvent A: 100:2:0.1 H2O/ACN/MeSO3H, solvent 
B: 100:2:0.1 ACN/H2O/MeSO3H, gradient: 0 min 0% B, 6 min 100%, 7 min 100%, 7.5 min 
0%, 9 min 0%, flow: 0,8 mL/min.) and UV detection at 210 nm. High resolution mass 
spectrometric identification of compounds was performed using SHIMADZU LCMS-IT-TOF 
ESI, WATERS SUNFIRE C18, 2.1 × 50 mm, 2.5 µm column (solvent A: 100:3 H2O/2-PrOH 
+ 0.05% HCOOH, solvent B: 95:5:3 H2O/ACN/2-PrOH + 0.05% HCOOH, gradient: 0 min 
0% B, 9 min 100%, 11 min 100%, 11.1 min 0%, 15 min 0%, flow: 0.7 mL/min.). Flash 
chromatography was performed on Teledyne ISCO CombiFlashRF instrument, using 
RediSept RF pre-packed silica gel columns and UV detection at 254 or 210 nm. Reagents and 
solvents were used as obtained from commercial suppliers without further purification. Yields 
refer to purified products and are not optimized. All tested compounds were >95% pure as 
assessed by LCMS and 1H NMR. 
 
2. Synthesis of compounds 
General procedure A [1-4] 
99 mg harmol (0.5 mmol) and 2 mmol of the appropriate alcohol were dissolved in 2 mL dry 
tetrahydrofuran, then 0.50 g triphenylphosphine on polymer (3.0 mmol/g, 1.5 mmol) was 
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added to the solution. After 10 minuntes 653 mg diethyl azodicarboxylate (1.5 mmol, 653 µL, 
~40% in toluene) was added. The mixture was stirred at r.t. under nitrogen until no further 
conversion was observed. The mixture was filtered, the polymer was washed with 
tetrahydrofuran, and the combined organic phases were evaporated under reduced pressure. 
The residue was purified via flash chromatography using hydrophilic interaction liquid 
chromatography.22 
[1]: 7-isopropoxy-1-methyl-9H-pyrido[3,4-b]indole 
Using 120 mg 2-propanol 44 mg 1 (37%) was obtained. 1H NMR (500 MHz, DMSO-d6) δ 
11.35 (s, 1H), 8.13 (d, J = 5.3 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 5.3 Hz, 1H), 6.98 
(d, J = 2.2 Hz, 1H) 6.81 (dd, J = 8.5, 2.2 Hz, 1h), 4.27 (sp, J = 6.0 Hz, 1H), 2.71 (s, 3H), 1.33 
(d, J = 6.0 Hz, 6H); 13C NMR (125 MHz, DMSO-d6) δ 158.6, 142.4, 141.7, 138.2, 135.0, 
127.7, 123.1, 115.2, 112.4, 110.7, 97.1, 70.0, 23.3, 20.8; HRMS calculated for C15H16N2O: 
240.1263; found 241.1329 (M+H). 
[2]: 1-methyl-7-(1-phenylethoxy)-9H-pyrido[3,4-b]indole  
Using 244 mg rac-1-phenylethanol and 3 eqivalent cyanomethylenetributylphosphorane 
instead of PPh3 and diethyl azodicarboxylate 91 mg 2 (60%) was obtained. 50 mg of the 
racemate was separated via chiral chromatography using Chiralpak AD column and 
ethanol/heptane (5:95) eluent. 2a refers to the earlier eluting enantiomer. 
2a: 24 mg; retention time: 76 min; 1H NMR (500 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.11 (d, J 
= 5.3 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 5.3 Hz, 1H), 7.46 (d, J = 8.3 Hz, 2H), 
7.36 (t, J = 7.7 Hz, 2H), 7.25 (t, J = 7.3 Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 6.87 (dd, J = 8.5, 
2.1 Hz, 1H), 5.60 (q, J = 6.4 Hz, 1H), 2.66 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 158.6, 143.6, 142.0, 141.7, 138.2, 134.9, 129.1, 127.9, 127.5, 126.1, 
123.0, 115.3, 112.4, 110.8, 97.5, 75.7, 25.0, 20.7. 
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2b: 23 mg; retention time: 112 min; 1H NMR (500 MHz, DMSO-d6) δ 11.30 (s, 1H), 8.11 (d, 
J = 5.3 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 5.3 Hz, 1H), 7.46 (d, J = 8.3 Hz, 2H), 
7.36 (t, J = 7.7 Hz, 2H), 7.25 (t, J = 7.3 Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 6.87 (dd, J = 8.5, 
2.1 Hz, 1H), 5.60 (q, J = 6.4 Hz, 1H), 2.66 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 158.6, 143.6, 142.0, 141.7, 138.2, 134.9, 129.1, 127.9, 127.5, 126.1, 
123.0, 115.3, 112.4, 110.8, 97.5, 75.7, 25.0, 20.7. 
[3]: 1-methyl-7-(2-pyridylmethoxy)-9H-pyrido[3,4-b]indole 
Using 218 mg 2-pyridinemethanol 120 mg 3 (92%) was obtained. 1H NMR (500 MHz, 
DMSO-d6) δ 11.40 (s, 1H), 8.60 (d, J = 4.6 Hz, 1H), 8.13 (d, J = 5.3 Hz, 1H), 8.06 (d, J = 8.7 
Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.79 (d, J = 5.3 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.35 (t, J 
= 6.2 Hz, 1H), 7.06 (d, J = 1.6 Hz, 1H), 6.94 (dd, J = 8.7, 1.6 Hz, 1H), 5.30 (s, 2H), 2.69 (s, 
3H); 13C NMR (125 MHz, DMSO-d6) δ 159.3, 157.2, 149.6, 142.2, 141.8, 138.2, 137.5, 135, 
127.6, 123.5, 123.2, 122.1, 115.6, 112.5, 110.1, 96.3, 71.0, 20.7; HRMS calculated for 
C18H15N3O: 289.1215; found 290.1287 (M+H). 
[4]: 1-methyl-7-[2-(2-pyridyl)ethoxy]-9H-pyrido[3,4-b]indole 
Using 244 mg 2-(2-hydroxyethyl)pyridine 121 mg 4 (79%) was obtained. 1H NMR (500 
MHz, DMSO-d6) δ 11.36 (s, 1H), 8.52 (d, J = 4.7 Hz, 1H), 8.22 (m, 1H), 8.12 (d, J = 5.3 Hz, 
1H), 8.01 (d, J = 8.6 Hz, 1H), 7.78 (d, J = 5.3 Hz, 1H), 7.74 (td, J = 7.6, 1.7 Hz, 1H), 7.40 (d, 
J = 7.6 Hz, 1H), 7.25 (dd, J = 7.3, 5.3 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 6.80 (dd, J = 8.6, 2.1 
Hz, 1H), 4.47 (t, J = 6.5 Hz, 2H), 3.25 (t, J = 6.5 Hz, 2H), 2.70 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 159.6, 149.6, 142.3, 141.7, 138.2, 137.0, 135.0, 127.6, 124.1, 123.1, 122.2, 
115.4, 112.4, 109.8, 95.8, 67.4, 37.6, 20.8; HRMS calculated for C19H17N3O: 303.1372; found 
304.1437  (M+H). 
 
General procedure B [5-8]  
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106 mg harmine (0.5 mmol) was dissolved in 2 mL dry DMF at 0 °C. 13.2 mg NaH (0.55 
mmol) was added to the solution in small portions and the mixture was stirred at 0 °C until it 
became clear. Then 0.55 mmol of the appropriate halide was added to the solution and the 
mixture was stirred further at same temperature until no further conversion was observed. The 
mixture was poured onto water, extracted with ethyl acetate, and the combined organic layers 
were dried over Na2SO4, filtered and concentrated under reduced pressure and the residue was 
purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 
solution and acetonitrile as eluents. 
[5]: 9-benzyl-7-methoxy-1-methyl-pyrido[3,4-b]indole 
Using 94 mg benzyl bromide 110 mg 5 (73%)was obtained; 1H NMR (500 MHz, DMSO-d6) 
δ 8.18 (d, J = 5.1 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 5.1 Hz, 1H), 7.28 (t, J = 7.4 
Hz, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.19 (d, J = 2.1 Hz, 1H), 6.92 (d, J = 7.4 Hz, 2H), 6.90 (dd, 
J = 8.6, 2.1 Hz, 1H), 5.89 (s, 2H), 3.82 (s, 3H), 2.73 (s, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 161.2, 143.8, 141.3, 139.5, 138.6, 135.4, 129.3, 129.0, 127.6, 125.8, 123.0, 114.7, 112.8, 
109.9, 94.2, 56.1, 47.7, 23.2. HRMS calculated for C20H18N2O: 302.1419; found 303.1487 
(M+H). 
[6]: 7-methoxy-9-[(3-methoxyphenyl)methyl]-1-methyl-pyrido[3,4-b]indole 
Using 111 mg 3-methoxybenzyl bromide 107 mg 6 (64%)was obtained; 1H NMR (500 MHz, 
DMSO-d6) δ 8.18 (d, J = 5.2 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 5.2 Hz, 1H), 7.18 
(d, J = 2.1 Hz, 1H), 7.18 (m, 1H), 6.90 (dd, J = 8.6, 2.1 Hz, 1H), 6.80 (m, 1H), 6.51 (m, 1H), 
6.41 (m, 1H), 5.85 (s, 2H), 3.83 (s, 3H), 3.65 (s, 3H), 2.74 (s, 3H); ); 13C NMR (125 MHz, 
DMSO-d6) δ 161.2, 160.0, 143.8, 141.3, 141.2, 138.6, 135.4, 130.5, 129.0, 123.0, 117.8, 
114.6, 112.8, 112.4, 112.0, 109.9, 94.2, 56.1, 55.4, 47.6, 23.2; HRMS calculated for 
C21H20N2O2: 332.1525; found 333.1583 (M+H). 
[7]: 7-methoxy-1-methyl-9-[[4-(trifluoromethyl)phenyl]methyl]pyrido[3,4-b]indole 
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Using 131 mg 4-(trifluoromethyl)benzyl bromide 153 mg 7 (83%) was obtained; 1H NMR 
(500 MHz, DMSO-d6) δ 8.20 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 5.2 
Hz, 1H), 7.68 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 6.92 (dd, 
J = 8.6, 2.1 Hz, 1H), 6.01 (s, 2H), 3.82 (s, 3H), 2.70 (s, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 161.3, 144.5, 143.7, 141.2, 138.8, 135.2, 129.2, 128.2, 126.7, 126.3, 124.7, 123.1, 114.7, 
112.9, 110.1, 94.1, 56.1, 47.4, 23.1; HRMS calculated for C21H17F3N2O: 370.1293; found 
371.1362 (M+H). 
[8]: 7-methoxy-1-methyl-9-[1-[4-(trifluoromethyl)phenyl]ethyl]pyrido[3,4-b]indole 
Using 139 mg rac-1-(1-bromoethyl)-4-(trifluoromethyl)benzene 180 mg 8 was obtained. 
HRMS calculated for C22H19F3N2O: 384.1449; found 385.1513 (M+H). The racemate was 
separated via chiral chromatography using Chiralcel OK column and EtOH/Heptane (30:70) 
eluent. 8a was isolated as the first eluting enantiomer. 
8a: 85 mg (44%); retention time: 32 min; 1H NMR (500 MHz, DMSO-d6) δ 8.26 (d, J = 5.2 
Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 5.2 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.52 (d, J 
= 8.2 Hz, 2H), 6.84 (dd, J = 8.7, 2.1 Hz, 1H), 6.65 (q, J = 7.0 Hz, 1H), 6.4 (br, 1H), 3.62 (s, 
3H), 2.91 (br, 3H), 2.01 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 160.0, 146.5, 
141.2, 140.9, 138.7, 135.9, 129.2, 128.3, 127.8, 126.0, 123.1, 116.1, 112.9, 109.2, 96.9, 55.6, 
53.6, 24.7, 18.1; 
8b: 87 mg (45%); retention time: 42 min; 1H NMR (500 MHz, DMSO-d6) δ 8.26 (d, J = 5.2 
Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 5.2 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.52 (d, J 
= 8.2 Hz, 2H), 6.84 (dd, J = 8.7, 2.1 Hz, 1H), 6.65 (q, J = 7.0 Hz, 1H), 6.4 (br, 1H), 3.62 (s, 
3H), 2.91 (br, 3H), 2.01 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 160.0, 146.5, 
141.2, 140.9, 138.7, 135.9, 129.2, 128.3, 127.8, 126.0, 123.1, 116.1, 112.9, 109.2, 96.9, 55.6, 
53.6, 24.7, 18.1; 
[9]: 7-methoxy-1-methyl-9-[2-[4-(trifluoromethyl)phenyl]ethyl]pyrido[3,4-b]indole 
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106 mg harmine (0.50 mmol), 85 mg 4’-trifluoromethyphenyl acetylene (0.50 mmol) and 3 
mg (0.05 mmol) KOH were dissolved in 1 mL dry dimethyl sulfoxide. The solution was 
stirred at 130 °C until no further conversion was observed. After the completion of the 
reaction the product was purified via preparative reversed phase chromatography using 5 mM 
aqueous NH4HCO3 solution and acetonitrile as eluents. The obtained intermediate (117 mg) 
was dissolved in ethanol and 10w/w% Pd/C was added. The reaction was run until completion 
in a pressure-boiler under 5 bar H2 at rt. The mixture was filtered and the filtrate evaporated to 
give 77 mg 9 (40% for 2 steps) in sufficient purity.1H NMR (500 MHz, DMSO-d6) δ 8.19 (d, 
J = 5.3 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.93 (d, J = 5.3 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 
7.43 (d, J = 8.0 Hz, 2H), 7.04 (d, J = 2.1 Hz, 1H), 6.84 (dd, J = 8.2, 2.1 Hz, 1H), 4.84 (t, J = 
7.4 Hz, 2H), 3.84 (s, 3H), 3.17 (t, J = 7.4 Hz, 2H), 2.97 (s, 3H); 13C NMR (125 MHz, DMSO-
d6) δ 161.1, 143.8, 143.3, 140.9, 137.8, 134.9, 130.4, 129.3, 127.7, 125.6, 122.9, 114.5, 
112.9, 110.1, 94.1, 55.9, 45.6, 36.3, 23.3; HRMS calculated for C22H19F3N2O: 384.1449; 
found 385.1520 (M+H). 
 
3. Preparation of ligand and protein sample solutions 
The 2 mM stock solutions of β-carbolines were prepared freshly before each measurement in 
dimethyl sulfoxide (DMSO). The volume of DMSO added into sample solutions never 
exceeded 5% (v/v) and caused negligible effects on the CD or fluorescence spectra. HSA 
(Sigma, 97%, essentially fatty acid-free) and AAG (Sigma) samples were dissolved in pH 7.4 
Ringer buffer solution (8.1 mM Na2HPO4·12H2O, 1.5 mM KH2PO4, 137 mM NaCl, 2.7 mM 
KCl, 0.8 mM CaCl2, 1.1 mM MgCl2). Genetic variants of AAG were separated following the 
chromatographic method of Hervé et al. as described previously.18 
 
4. HSA binding test by affinity chromatography 
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Chromatographic experiments on HSA-Sepharose gel were performed as described 
previously, using oxazepam acetate, lorazepam acetate enantiomers and diazepam as 
reference compounds.23 Elution volume of harmine and its derivatives were detected at 280 
nm. Control experiments were performed on a gel containing no HSA. Compounds 2 and 7-9 
showed some non-specific adsorption. 
 
5. Fluorescence spectroscopic measurements 
Fluorescence measurements were carried out in a JASCO FP 8300 spectrofluorimeter at 23 ± 
1 °C, using a quartz cuvette with 1 cm optical path length; both excitation and emission 
bandwidths were set at 5 nm. The β-carbolines were excited at 320 nm. Intensities were 
corrected for the inner filter effect according to the absorbance of the added alkaloids at both 
the excitation and the emission wavelengths. The association binding constants at 1:1 
stoichiometry were calculated from the fluorescence emission increase of the protein bound 
alkaloids using the following equation (non-linear regression analysis with Microcal Origin 
ver. 8.6): 
 
where [P]t ,[L]t are the total concentration of the protein and ligand; fp, fl, fpl are the specific 
fluorescence of the protein, ligand and complex.24 
 
6. Circular dichroism and UV absorption spectroscopy measurements 
CD and UV absorption spectra were recorded on a JASCO J-715 spectropolarimeter at 25 ± 
0.2 °C. Temperature control was provided by a Peltier thermostat equipped with magnetic 
stirring. Rectangular quartz cells of a 1 cm optical path length (Hellma, USA) were used. 
Each spectrum represents the average of three scans obtained by collecting data at a scan 
speed of 100 nm/min. Absorption spectra were obtained by conversion of the high voltage 
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(HT) values of the photomultiplier tube of the CD equipment into absorbance units. CD and 
absorption curves of ligand-protein mixtures were corrected by subtracting the spectra of 
ligand-free protein solutions. JASCO CD spectropolarimeters record CD data as ellipticity 
(Θ) in units of millidegrees (mdeg). Details of the estimation of the association constant (Ka) 
and the number of binding sites (n) using CD spectroscopic data have been described 
elsewhere.25 Non-linear regression analysis of the induced CD values measured at increasing 
[ligand]/[protein] molar ratios was performed by Microcal Origin 8.6 Pro (OriginLab 
Corporation, Northhampton, MA). 
 
7. Molecular docking calculations 
All calculations were performed using DockingServer.26 PM6 semi-empirical method 
(MOPAC2009) was used for energy minimization and partial charges calculation to the 
neutral form of compound 4. X-ray structure of the “A” variant of AAG (PDB code 3APU) 
was selected. All water molecules were removed from the protein coordinates prior to 
docking calculations. Hydrogen atoms were added to the PDB structure using 
AutoDockTools. The total charge of AAG and partial charges of the atoms were calculated by 
the Mozyme function of MOPAC2009 software. The calculated partial charges were applied 
for further calculations. Sequential ligand docking was carried out, initial position and 
orientation of compound 4 were set randomly. The first molecule was docked using a pre-
evaluated interaction grid based on interactions with atoms in the protein alone. The second 
ligand was then docked employing an interaction grid including interactions with the protein 
and bound configurations of the first ligand. Affinity (grid) maps of 25 × 25 × 25 Å grid 
points were generated using the Autogrid program. AutoDock parameter set- and distance-
dependent dielectric functions were used in the calculation of the van der Waals and the 
electrostatic terms, respectively. Docking simulations were performed using the Lamarckian 
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genetic algorithm and the Solis & Wets local search method. Each docking experiment was 
derived from 100 different runs which were set to terminate after a maximum of 2500000 
energy evaluations. The population size was set to 150. During the search, a translational step 
of 0.2 Å, and quaternions and torsion steps of 5 were applied. The outputs of docking 
calculations were rendered with PyMOL (The PyMOL Molecular Graphics System, DeLano 
Scientific LLC, Palo Alto, CA, USA. http://www.pymol.org). 
 
8. pKa Prediction 
Calculator Plugin of the software MarvinSketch version 6.3.0 (2014, ChemAxon, 
http://www.chemaxon.com) was used to estimate the pKa values of harmine and its synthetic 
derivatives. 
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Results and discussion 
 
HSA binding studies by affinity chromatography 
HSA interaction of harmine and its nine synthetic analogues were evaluated from their 
retentions on a HSA-Sepharose column, where the elution volume is characteristic of the 
overall binding affinity (ΣnKa). Results showed that harmine binds weakly to HSA (Ka ~ 2.5 × 
104 M-1) and the methoxy-isopropyloxy group replacement (compound 1) caused only a slight 
affinity increase (Table 1). A similar result (Ka ~ 2.4 × 10
4 M-1) was found for the HSA 
binding of harmane15 which lacks a methoxy substituent of harmine. For harmine-bovine 
serum albumin interaction also weak binding was reported (Ka ~ 2.0 × 10
4 M-1).27 Introducing 
aromatic substituents in position 7, however, resulted in considerably enhanced albumin 
binding affinities. Compound 2 showed about ten times stronger association compared to 
harmine, without significant enantioselectivity. In case of compounds 3 and 4 having a 
pyridine ring in their R7 substituent, the Ka values are only about four times higher than that of 
harmine. Aromatic substitution on the pyrrole nitrogen provoked even stronger enhancement, 
association constant values of compounds 5-9 are about 4.0 × 105 M-1. The enantiomers of 
compound 8 showed no stereospecific binding, either. The enhanced HSA affinity of the more 
hydrophobic harmine derivatives may be beneficial since the overall solubility of the drugs in 
plasma will increase. Furthermore, tight albumin association may improve the chemical as 
well as the metabolic stability of the alkaloids28 and can facilitate their uptake in growing 
tumor tissues where albumin molecules are increasingly taken up by cancer cells.29 However, 
the efficacy of drugs can be compromised by extensive HSA binding since only the unbound 
fraction exhibits pharmacologic effects. The highest HSA affinity constants obtained in this 
study predict no serious limitation for the pharmacological activity of the harmine derivates 
that is also impacted by other factors such as tissue binding, stability, and clearance.30,31   
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Protein binding studies by fluorescence spectroscopy 
Harmine and its derivatives, like other β-carbolines, are highly fluorescent compounds. 
Fluorescence properties of the cationic and neutral forms are different, and this phenomenon 
can be utilized in protein binding studies, as shown previously for the HSA association of 
harmane and norharmane. 15,28 The cationic species fluoresces strongly with a peak maximum 
centred ~430 nm while the blue shifted emission of the neutral molecules is much weaker 
centered around 350 nm. The experimentally determined pKa of harmine is 7.45.
32 The use of 
this value in the Henderson-Hasselbalch equation at pH 7.4 gives rise to 53 and 47 per cent 
for the neutral and cationic form of harmine. Since the protonation constants of the synthetic 
derivatives are unknown, calculated pKa values are shown in the Supplementary Information. 
As expected, the substitutions made in the 7 and 9 positions do not alter significantly the 
basicity of the pyridine nitrogen in relation to that of harmine suggesting very similar neutral-
cationic equilibrium for the derivatives. The fluorescence approach was employed to 
investigate the AAG binding properties of harmine and its derivatives. Figure 1 shows the 
change of the fluorescence emission of harmine upon addition of AAG. The ligand solution at 
pH 7.4 displays a single, unstructured band at 421.5 nm, assigned to the emission of the 
cationic form due to the well-studied excited state pKa shift of β-carbolines.
33 Increasing 
concentration of AAG induces intensity decrease with simultaneous development of a new 
band with a maximum around 349 nm, indicating the bound neutral form of harmine. An 
isoemission point appears around 379 nm suggesting the co-existence of the bound and free 
species at equilibrium. Based on the emission data at 349 nm, a value of Ka ~ 3.3 × 10
4 M-1 
could be calculated, which is close to that measured for HSA binding of harmine (Table 1).  
Similar experiments, comparing the binding of compound 7 to AAG and HSA can be seen in 
Fig. 2. Analysis of the low intensity emission data of the HSA bound neutral species at 366 
nm yielded a Ka value of 3.1 × 10
5 M-1 for HSA, which is in good agreement with the affinity 
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constant obtained on the HSA column. The fluorescence changes measured with AAG, 
however, prove about eight times stronger AAG binding (Ka ~ 2.4 × 10
6 M-1). It is to be noted 
that the satisfactory concordance between the HSA affinity constants of additional harmine 
derivatives estimated by affinity chromatography method as well as from fluorescence 
emission of the protein bound neutral species (Table 1) refers to the decisive contribution of 
the neutral form in the binding process. 
Due to genetic polymorphism, AAG isolated for is a 70:30 mixture of two genetic variants, 
called F1/S and A, having different drug binding properties. The binding of compounds 7 and 
4 to the separated F1/S and A variants was examined, too. In case of 7 we observed (Fig. 3) 
that addition of the F1/S variant to the ligand solution gave rise to more pronounced 
fluorescence changes than the same amount of the A variant, corresponding to ten times 
higher affinity on the F1/S variant compared to the A (Table 1). By monitoring the 
fluorescence spectral changes of 4 upon addition of the genetic variants, the descending 
emission of the peak at 422 nm could be observed, however, the short-wavelength band 
corresponding to the neutral form evolved only in presence of the F1/S variant (Fig. 3). 
Therefore, in case of the A variant the fluorescence method was not adequate to calculate the 
association constant, but it demonstrates different affinity of is ligand for the genetic variants 
of AAG. 
AAG affinity data derived for harmine and its derivatives are summarized in Table 1. The 
binding of harmine is weak, similarly to its HSA binding. Substitution in position 9 with 
aralkyl groups, besides enhancing their cytotoxic activity in general, also increased the 
interaction with plasma proteins. The replacement of the methoxy group by alkoxy and 
(het)aryl alkoxy substituents in position 7 has a similar effect. Compared to harmine, this 
modification resulted in a four to ten times higher AAG affinity (Table 1). It is to be noted, 
that the HSA interaction of compounds possessing a pyridine moiety was weaker. The 
Page 22 of 43RSC Advances
17 
 
configuration of the stereocenter of 2 or 8 had negligible effect on protein binding. The AAG 
affinity of compounds 5-9 bearing a benzyl-type substituent on the indole nitrogen (R9) was 
high (Ka ~ 10
6 M-1). The substitution of the phenyl ring had only minor influence on the 
binding. The highest affinities were measured for the 4-trifluoromethyl substituted analogues, 
while the 3-methoxy group reduced the binding. 
 
Circular dichroism and UV absorption spectroscopic investigation on the binding of 
derivatives 4 and 7 to AAG 
HSA binding of the optically inactive β-carboline derivatives studied in this work induced no 
or poor quality CD bands in the respective light absorption region of the ligands (data not 
shown). Therefore, the induced CD spectroscopic approach15,34,35 could not be employed for 
estimation of the HSA association constants. In contrast to this, entrapment of some alkaloids 
within the central drug binding pocket of AAG induced salient CD activity. Addition of the 7-
pyridylethoxy derivative of harmine (4) to the A genetic variant of AAG induced several CD 
signals between 240 and 400 nm (Fig. 4). Two weaker, opposite signals can be seen at 303 
and 360 nm which are allied to the broad absorption band displayed above 280 nm. In the 
short-wavelength region a more intense, negative-positive CD band pair was resolved with a 
zero cross-over point around 253 nm. Magnitudes of these induced CD peaks increased 
proportionally with the increasing concentration of the ligand but neither their shape nor their 
position showed variations during the titration. Comparison of the UV spectra of the free and 
AAG bound form of 4 recorded at the same concentration indicates large intensity reduction 
of the absorption values (green and black curves in Fig. 5). This phenomenon, called 
hypochromism, suggests the π-π stacking of two carboline rings at the binding site of AAG. 
Due to the asymmetry of the protein environment, the stacked, planar aromatic moieties 
cannot be arranged in a completely parallel fashion but their long axis are rotated relative to 
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each other, forming a helical array. This situation results in a chiral intermolecular exciton 
coupling between the π-π* transition moments of the proximal carboline chromophores 
generating two intense, opposite CD bands associated to the respective UV absorption peak 
(Fig. 4). As it follows from the exciton chirality rule,36 the negative-positive order of these 
signals predicts the M-helicity of the stacked dimer accommodated within the central cavity of 
AAG. The less intense ellipticity bands of 4 measured above 290 nm may also be of excitonic 
origin. The dimeric binding mode of 4 inferred from the spectroscopic results is supported by 
the analysis of the CD titration data. The best fit on the experimental values was obtained 
using 2:1 ligand:protein binding stoichiometry. The estimated affinity constants refer to tight 
interaction of 4 with both genetic variants of AAG (Table 1). 
It is to be noted that apart from the hypochromism, the overall UV absorption profile of 
compound 4 measured with the A variant of AAG shows the relative dominance of the neutral 
species but binding in the charged form also occurs (Fig. 5). Binding preference for the 
unprotonated ligand is more pronounced in the presence of the F1/S variant, where the UV 
profile of the bound ligand is very similar to the observed in alkaline solution (Fig. 5). The 
weaker hypochromism and the less intense induced CD bands (data not shown) suggest that 
the F1/S protein also binds two alkaloid molecules but with a larger intermolecular distance 
between them. 
Taking into consideration these data, the very low fluorescence emission of the neutral 
species of compound 4 obtained with the A variant (Fig. 3) might in part be attributed to its 
mixed, neutral-cationic binding and also to a dimerization caused self-quenching 
mechanism.37 
Interestingly, the AAG binding behaviour of 4 is highly reminiscent to that of acridine orange, 
the association of which to the A variant also occurs in a dimeric form inducing a 
characteristic biphasic CD pattern.19 Similarly to compound 4, F1/S binding of the acridine 
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orange results in much weaker exciton signals. Comparison of the crystal structures of the 
genetic variants revealed that the central drug binding pocket is narrower in the A form.38 
Instead of the three sub-chambers present in F1/S, the A variant possesses only two binding 
lobes. It follows that due to steric restrictions, co-binding of two molecules of compound 4 
can occur only in a tightly stacked, dimeric configuration while the larger cleft of the F1/S 
variant allows greater room and separation of the carboline moieties. The pyridine side chain 
seems to be important for the dimeric binding mode since the harmine-AAG interaction did 
not produce the above spectroscopic features (hypochromism, exciton CD coupling). 
As the fluorescence measurements showed, compound 7 bearing a trifluorophenyl substituent 
attached to the indole nitrogen also exhibits selective AAG binding in favour of the F1/S 
variant (Fig. 3). This behaviour is reflected in the distinct CD and absorption spectroscopic 
changes obtained with the genetic variants, too (Fig. 6). The F1/S form binds preferentially 
the neutral species of the molecule which is attested by the great similarity between the UV 
curves recorded in 0.1 M NaOH and in pH 7.4 buffer solution of the protein. In relation to the 
absorption spectrum measured in buffer, the A variant provoked limited changes only 
suggesting that its cationic-neutral discrimination ability is much weaker than that of the F1/S 
form. Due to the more uniform, tighter association of compound 7 to the F1/S variant, higher 
intensity ellipticity signals were induced than that measured with the A form (Fig. 6). 
Distinctly from 4, the bulky trifluoromethyl-phenyl moiety sterically restricts the dimeric 
binding of 7. Similarly to various AAG ligands having a rigid, planar ring system, the 
observed CD activity of 7 may be induced through non-degenerate exciton coupling with 
high-energy π-π* transitions of adjacent aromatic side chains of the binding pocket.39,40  
 
Sequential molecular docking of compound 4 to the A variant of AAG 
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Computational docking calculation was also performed to obtain insight into the molecular 
details of the AAG association of compound 4. Taking into account the CD and UV 
spectroscopic results, two molecules of compound 4 were docked sequentially into the 
binding room of AAG. The most frequent and best energy result shows a pair of partially π-
stacked ligand molecules in the binding crevice stabilized by four intermolecular H-bonds 
(Fig. 7). The interplanar distance between the β-carboline skeletons is about 4 Å and their 
long axes close a counterclockwise, left-handed angle. This binding geometry is favourable 
for dipole-dipole coupling between the π-π* transitions of the β-carboline chromophores, 
which is consistent with the induced CD exciton couplet and the UV hypochromism of the 
AAG bound species (Fig. 4). Considering the exciton chirality rule,36 the left-handed 
orientation of the ligand molecules predicts a longer-wavelength negative and a shorter-
wavelength positive CD band pair which is in full accordance with the measured 
spectroscopic data. 
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Conclusions 
 
In the present study, the synthesis of a series of novel harmine derivatives bearing an arylated 
alkoxy substituent in position 7, or a modified benzyl moiety in position 9 was described. 
Plasma protein binding of these β-carboline analogues was found to be substituent-dependent. 
Incorporation of the aromatic pharmacophore group into the positions 7 or 9 of the carboline 
skeleton brought about considerably enhanced affinity to both HSA and AAG. These results 
imply that the pharmacologically active, free serum levels of these potential therapeutic 
agents are supposed to be very low that should be taken into consideration during further drug 
development phases. In contrast to the well documented cationic drug binding preference of 
AAG, the spectroscopic results proved that the AAG association of β-carbolines possessing 
basic pyridine nitrogen takes place mainly in non-protonated form. Moreover, the 7-
pyridylethoxy derivative of harmine exhibited π-stacked, dimeric binding to the A but not to 
the F1/S variant of AAG that is related to the distinct architecture of the internal cavity of 
their β-barrels. 
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Compound 
Substituent                    Ka (M
-1
) 
–R7 –R9 HSA (ac) AAG(fl) 
Harmine Me H 2.5 × 104 3.3 × 104  
1  H 3.5 × 10
4
 n.d. 
2a* 
 
H 2.2 × 105 1.3 × 105  
2b* 
 
H 2.7 × 105 1.3 × 105  
3 
 
H 
9.0 × 104 
8.4 × 104 (fl) 
3.3 × 105 
4 
 
H 
9.0 × 104 
9.4 × 104 (fl) 
4.1 × 105  (F1/S) (cd) 
3.4 × 105 (A) (cd) 
5 Me  
4.0 × 105 
7.2× 105 (fl) 
1.6 × 106 
6 Me 
 
4.3 × 105 
4.0 × 105 (fl) 
8.0 × 105  
7 Me  
4.0 × 105 
3.1 × 105 (fl) 
4.1 × 106  (F1/S) 
3.9 × 105 (A) 
8a* Me  
3.9 × 105 
2.1 × 105 (fl) 
1.2 × 106 
8b* Me  3.5 × 10
5 7.0 × 105   
9 Me 
 
3.2 × 105 
1.1 × 105 (fl) 
2.8 × 106   
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*The assignment of the chirality is arbitrary and it is only used to denote the stereochemical 
relationship of compounds 2a-2b and 8a-8b. 
 
Table 1 
HSA and AAG association constants of harmine and its synthetic derivatives estimated by 
affinity chromatography (ac), fluorescence (fl), and circular dichorism (cd) spectroscopy 
methods. n.d: not determined. 
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Scheme 1.  
General chemical structure of harmine (R7: CH3- and R9: H) and itsd derivatives  showing the equilibrium 
between the protonated and nonprotonated forms (the pKa of harmine is 7.45). The R7 and R9 notations 
represent the frequently substituted positions.  
886x213mm (72 x 72 DPI)  
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Figure 1.  
Emission spectra of harmine measured in AAG solution at increasing protein/ligand molar ratios (2 mL of 
harmine solution was titrated with 200 µM AAG dissolved in the ligand solution). Fluorescence intensities 
plotted against the AAG concentration of the sample solution. The solid line is the result of non-linear fitting 
analysis.  
278x186mm (300 x 300 DPI)  
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Figure 2.  
Fluorescence emission spectral changes of compound 7 as a function of HSA and AAG concentration (2 mL 
of 2 µM ligand solution was titrated with aliquots of 80 µM HSA and AAG dissolved in the ligand stock 
solution).  
287x201mm (300 x 300 DPI)  
 
 
Page 35 of 43 RSC Advances
  
 
 
Figure 3.  
Comparison of the emission spectral changes of compounds 7 and 4 in the presence of the F1/S and A 
genetic variant of AAG (2 mL of ligand solutions were titrated with 80 µM AAG variants dissolved in the 
ligand stock solution).  
287x201mm (300 x 300 DPI)  
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Figure 4.  
Difference CD and UV absorption spectra of compound 4 added to 25 µM buffer solution of the A genetic 
variant of AAG.  
599x814mm (72 x 72 DPI)  
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Figure 5.  
Comparison of the UV absorption spectra of compound 4 measured in protein-free solutions at different pH 
values and in the presence of the A and F1/S genetic variant of AAG (Ringer buffer).  
597x459mm (72 x 72 DPI)  
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Figure 6.  
Difference CD and UV absorption spectra of compound 7 measured with the F1/S and A genetic variant of 
AAG. UV curves of the ligand recorded in protein-free solutions at different pH values are also shown.  
657x896mm (72 x 72 DPI)  
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Figure 7.  
Two compound 4 molecules docked sequentially into the binding cavity of the “A” variant of AAG. Dotted 
lines indicate intermolecular H-bonds.  
211x211mm (72 x 72 DPI)  
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Compound 
Substituents pKa 
 
–R7 –R9 (25 °C) 
Harmine  H 6.15 
1 
 
H 6.15 
2a 
 
H 6.15 
2b 
 
H 6.15 
3 
 
H 6.15 
4 
 
H 6.15 
5 Me 
 
6.09 
6 Me 
 
6.09 
7 Me 
 
6.09 
8a Me 
 
6.08 
8b Me 
 
6.08 
9 Me 6.10 
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Supplementary Table 1 
The pKa values of harmine and its synthetic derivatives predicted with MarvinSketch version 
6.3.0 (ChemAxon). 
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